NORVIUM BIOSCIENCE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NORVIUM BIOSCIENCE, and when can generic versions of NORVIUM BIOSCIENCE drugs launch?
NORVIUM BIOSCIENCE has two hundred and forty-seven approved drugs.
There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.
There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and forty-one supplementary protection certificates in seventeen countries.
Summary for NORVIUM BIOSCIENCE
International Patents: | 51 |
US Patents: | 4 |
Tradenames: | 197 |
Ingredients: | 185 |
NDAs: | 247 |
Drugs and US Patents for NORVIUM BIOSCIENCE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Norvium Bioscience | GABAPENTIN | gabapentin | TABLET;ORAL | 090335-001 | Jun 1, 2010 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Norvium Bioscience | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | CAPSULE;ORAL | 075564-002 | Oct 27, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Norvium Bioscience | NAPROXEN SODIUM | naproxen sodium | TABLET;ORAL | 074367-002 | Aug 31, 1994 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Norvium Bioscience | TERAZOSIN HYDROCHLORIDE | terazosin hydrochloride | CAPSULE;ORAL | 075140-002 | Feb 11, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Norvium Bioscience | ROPINIROLE HYDROCHLORIDE | ropinirole hydrochloride | TABLET;ORAL | 078881-003 | May 5, 2008 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
Norvium Bioscience | CLARITHROMYCIN | clarithromycin | TABLET;ORAL | 065195-001 | Mar 11, 2005 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NORVIUM BIOSCIENCE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-002 | Aug 23, 1993 | RE30633 | ⤷ Subscribe |
Norvium Bioscience | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | ⤷ Subscribe |
Norvium Bioscience | LUXIQ | betamethasone valerate | AEROSOL, FOAM;TOPICAL | 020934-001 | Feb 28, 1999 | 6,126,920 | ⤷ Subscribe |
Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-003 | Aug 23, 1993 | 4,822,807 | ⤷ Subscribe |
Norvium Bioscience | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | 4,952,586 | ⤷ Subscribe |
Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-001 | Aug 23, 1993 | RE30633 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NORVIUM BIOSCIENCE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Inhalation Solution | 0.021% and 0.042% | ➤ Subscribe | 2005-10-19 |
➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2006-12-13 |
➤ Subscribe | Nasal Spray | 0.125 mg base/spray | ➤ Subscribe | 2005-11-14 |
International Patents for NORVIUM BIOSCIENCE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | PI0514806 | ⤷ Subscribe |
Poland | 1796636 | ⤷ Subscribe |
Eurasian Patent Organization | 014372 | ⤷ Subscribe |
European Patent Office | 2438910 | ⤷ Subscribe |
European Patent Office | 2289512 | ⤷ Subscribe |
Norway | 339620 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NORVIUM BIOSCIENCE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663240 | 59/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
2822954 | SPC/GB18/031 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
0914118 | PA2007001 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828 |
1506211 | C 2014 029 | Romania | ⤷ Subscribe | PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
1412357 | 77 5006-2008 | Slovakia | ⤷ Subscribe | PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408 |
1453521 | 132016000025143 | Italy | ⤷ Subscribe | PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.